LSL Pharma Group Income Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Jul '21 Jul 31, 2021
Revenue	26.8	17.75	10.03	8.21	-
Revenue Growth (YoY)	69.41%	76.98%	22.08%	-	-
Cost of Revenue	18.83	12.4	8.38	10.39	-
Gross Profit	7.97	5.35	1.65	-2.17	-
Selling, General & Admin	6.4	4.52	3.64	3.92	-
Research & Development	-	-	-	0.67	-
Other Operating Expenses	0.15	0.42	4.67	0.43	0.06
Total Operating Expenses	6.56	4.94	8.31	5.01	0.06
Operating Income	1.57	0.82	-2	-13.94	-0.06
Interest Expense	-2.65	-1.9	-1.81	-0.88	-3.1
Other Non-Operating Income (Expense)	4.06	4.86	-	-	-
Total Non-Operating Income (Expense)	1.41	2.96	-1.81	-0.88	-3.1
Pretax Income	2.98	3.37	-8.47	-8.06	-3.16
Provision for Income Taxes	-	0.05	-	-	-
Net Income	2.78	3.32	-8.47	-8.06	0.09
Net Income to Common	2.78	3.32	-8.47	-8.06	0.09
Shares Outstanding (Basic)	93	105	80	67	21
Shares Outstanding (Diluted)	93	105	80	67	21
Shares Change (YoY)	-24.55%	31.18%	19.66%	225.39%	-
EPS (Basic)	0.03	0.03	-0.11	-0.12	0.00
EPS (Diluted)	0.03	0.03	-0.11	-0.12	0.00
Free Cash Flow	-3.56	-4.77	-7.73	-4.16	0
Free Cash Flow Per Share	-	-0.05	-0.10	-	-
Gross Margin	29.73%	30.13%	16.40%	-26.44%	-
Operating Margin	5.85%	4.64%	-19.93%	-169.70%	-
Profit Margin	11.11%	18.69%	-84.48%	-98.15%	-
FCF Margin	-13.27%	-26.89%	-77.04%	-50.66%	-
EBITDA	3.83	2.33	-0.87	-12.89	-0.06
EBITDA Margin	14.28%	13.15%	-8.68%	-156.95%	-
EBIT	1.57	0.82	-2	-13.94	-0.06
EBIT Margin	5.85%	4.64%	-19.93%	-169.70%	-
Effective Tax Rate	-	1.49%	0.00%	0.00%	0.00%

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.